循环CD45RO+CD8+记忆T细胞比例与伊匹木单抗治疗的黑色素瘤患者临床缓解相关
该前瞻性研究纳入30例接受伊匹木单抗(n=21)或帕博利珠单抗(n=9)治疗的黑色素瘤患者,在免疫检查点阻断前4个周期及首次肿瘤评估前检测外周血。基线CD45RO+CD8+ T细胞≤25%者未对伊匹木单抗产生缓解,基线水平正常者接受伊匹木单抗后总生存显著更长,但该关联未见于帕博利珠单抗。
要点
- 13例(43%)基线CD45RO+CD8+ T细胞水平正常,17例(57%)水平偏低。
- 基线CD45RO+CD8+ T细胞≤25%的患者对伊匹木单抗治疗无缓解。
- 基线CD45RO+CD8+ T细胞水平正常者接受伊匹木单抗后总生存显著更长。
核心结论
- 基线CD45RO+CD8+ T细胞水平正常的患者对伊匹木单抗治疗的缓解频率显著更高,其CD8+ T细胞似乎呈抗原非特异性激活。
- 基线CD45RO+CD8+ T细胞水平是有望预测伊匹木单抗缓解的生物标志物。
研究设计与样本
- 前瞻性研究,纳入30例接受伊匹木单抗(n=21)和帕博利珠单抗(n=9)治疗的黑色素瘤患者。
- 在免疫检查点阻断前4个周期及首次肿瘤评估前,采集临床数据、血液学参数和新鲜分离的外周血单个核细胞。
主要发现
- 13例(43%)患者基线CD45RO+CD8+ T细胞水平正常,17例(57%)患者基线CD45RO+CD8+ T细胞水平偏低。
- 基线CD45RO+CD8+ T细胞水平与伊匹木单抗的缓解显著相关,但与帕博利珠单抗的缓解不相关。
- 基线CD45RO+CD8+ T细胞≤25%的患者对伊匹木单抗治疗无缓解。
- 伊匹木单抗治疗患者的CD8+ T细胞呈现活化的HLA-DR+CD25-表型,提示抗原非特异性刺激。
- HLA-DR+CD25-CD8+ T细胞水平在基线CD45RO+CD8+ T细胞正常的患者中显著更高,且在治疗期间进一步显著升高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immune checkpoint blockade (ICB) has been a breakthrough in the treatment of metastatic melanoma. But with only about 20-40% long-term responders and severe side-effects in about 12-17%, finding predictive markers for treatment response is of great interest. METHODS: We prospectively assessed clinical data, haematologic parameters and freshly isolated peripheral blood mononuclear cells of 30 patients treated with ipilimumab (n = 21) and pembrolizumab (n = 9) prior to the first 4 cycles with ICB and before the first tumour assessment. RESULTS: We discovered that the baseline levels of CD45RO+CD8+ T cells significantly differed among the patients. Thirteen (43%) of our patients had normal baseline levels of CD45RO+CD8+ T cells, whereas 17 (57%) patients were low on CD45RO+CD8+ T cells. The baseline levels of CD45RO+CD8+ T cells correlated significantly with the response to ipilimumab but not pembrolizumab. Patients with baseline levels of lower/equal 25% of CD45RO+CD8+ T cells did not respond to treatment with ipilimumab. Phenotyping the CD8+ T cells in patients treated with ipilimumab revealed an activated HLA-DR+CD25- phenotype, implying antigen non-specific stimulation. The levels of the HLA-DR+CD25-CD8+ T cells were significantly higher in patients with a normal baseline of CD45RO+CD8+ T cells and even increased significantly during treatment. Furthermore, proliferation of melanoma antigen recognized by T cells 1 (MART-1)-specific CD8+ T cells was not observed. Patients with normal baseline levels of CD45RO+CD8+ T cells showed a significant longer overall survival when treated with ipilimumab but not pembrolizumab. CONCLUSION: Patients with normal baseline levels of CD45RO+CD8+ T cells respond significantly more frequently to treatment with ipilimumab and the CD8+ T cells appear to be antigen non-specifically activated. The baseline level of CD45RO+CD8+ T cells represents a promising factor as biomarker for the prediction of the response to ipilimumab.
引用
- Tietze JK, Angelova D, Heppt MV, et al. The proportion of circulating CD45RO+CD8+ memory T cells is correlated with clinical response in melanoma patients treated with ipilimumab. Eur J Cancer. 2017. PMID: 28242504. doi:10.1016/j.ejca.2016.12.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。